

References

1. Huang AT, Garcia-Carreras B, Hitchings MDT, Yang B, Katzelnick LC, Rattigan SM, et al. A systematic review of antibody mediated immunity to coronaviruses: kinetics, correlates of protection, and association with severity. *Nat Commun*. 2020 Sep 17;11(1):4704. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32943637>
2. Post N, Eddy D, Huntley C, van Schalkwyk MCI, Shrotri M, Leeman D, et al. Antibody response to SARS-CoV-2 infection in humans: A systematic review. *PLoS One*. 2020;15(12):e0244126. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33382764>
3. Shrotri M, van Schalkwyk MCI, Post N, Eddy D, Huntley C, Leeman D, et al. T cell response to SARS-CoV-2 infection in humans: A systematic review. *PLoS One*. 2021;16(1):e0245532. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33493185>
4. Hellerstein M. What are the roles of antibodies versus a durable, high quality T-cell response in protective immunity against SARS-CoV-2? *Vaccine X*. 2020 Dec 11;6:100076. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32875286>
5. Letko M, Marzi A, Munster V. Functional assessment of cell entry and receptor usage for SARS-CoV-2 and other lineage B betacoronaviruses. *Nat Microbiol*. 2020 Apr;5(4):562-9. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/32094589>
6. Bertoletti A, Tan AT, Le Bert N. The T-cell response to SARS-CoV-2: kinetic and quantitative aspects and the case for their protective role. *Oxford Open Immunology*. 2021;2(1) Available at: <https://doi.org/10.1093/oxfimm/iqab006>
7. Grigoryan L, Pulendran B. The immunology of SARS-CoV-2 infections and vaccines. *Semin Immunol*. 2020 Aug;50:101422. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33262067>
8. Reynolds CJ, Pade C, Gibbons JM, Butler DK, Otter AD, Menacho K, et al. Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose. *Science*. 2021 Apr 30 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33931567>
9. Cromer D, Juno JA, Khoury D, Reynaldi A, Wheatley AK, Kent SJ, et al. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection. *Nat Rev Immunol*. 2021 Apr 29 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33927374>
10. Hartley GE, Edwards ESJ, Aui PM, Varese N, Stojanovic S, McMahon J, et al. Rapid generation of durable B cell memory to SARS-CoV-2 spike and nucleocapsid proteins in COVID-19 and convalescence. *Sci Immunol*. 2020 Dec 22;5(54) Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33443036>
11. Lau EHY, Tsang OTY, Hui DSC, Kwan MYW, Chan WH, Chiu SS, et al. Neutralizing antibody titres in SARS-CoV-2 infections. *Nat Commun*. 2021 Jan 4;12(1):63. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33397909>
12. Dan JM, Mateus J, Kato Y, Hastie KM, Yu ED, Faliti CE, et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection. *Science*. 2021 Feb 5;371(6529) Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33408181>
13. Tarke A, Sidney J, Methot N, Zhang Y, Dan JM, Goodwin B, et al. Negligible impact of SARS-CoV-2 variants on CD4 (+) and CD8 (+) T cell reactivity in COVID-19 exposed donors and vaccinees. *bioRxiv*. 2021 Mar 1 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33688655>
14. Health Information and Quality Authority (HIQA). Duration of immunity (protection from reinfection) following SARS-CoV-2 infection - 8 March 2021. Dublin: HIQA; 2021. Available at: https://www.hiqa.ie/sites/default/files/2021-03/Duration-of-protective-immunity_Evidence-Summary.pdf
15. Lumley SF, O'Donnell D, Stoesser NE, Matthews PC, Howarth A, Hatch SB, et al. Antibody Status and Incidence of SARS-CoV-2 Infection in Health Care Workers. *N Engl J Med*. 2021 Feb 11;384(6):533-40. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33369366>
16. Hall VJ, Foulkes S, Charlett A, Atti A, Monk EJM, Simmons R, et al. SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN). *Lancet*. 2021 Apr 17;397(10283):1459-69. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33844963>
17. Abu-Raddad LJ, Chemaitelly H, Coyle P, Malek JA, Ahmed AA, Mohamoud YA, et al. SARS-CoV-2 reinfection in a cohort of 43,000 antibody-positive individuals followed for up to 35 weeks. *medRxiv*. 2021;2021.01.15.21249731. Available at: <https://www.medrxiv.org/content/medrxiv/early/2021/01/15/2021.01.15.21249731.full.pdf>
18. Hanrath AT, Payne BAI, Duncan CJA. Prior SARS-CoV-2 infection is associated with protection against symptomatic reinfection. *J Infect*. 2021 Apr;82(4):e29-e30. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33373652>
19. Harvey RA, Rassen JA, Kabelac CA, Turenne W, Leonard S, Klesh R, et al. Real-world data suggest antibody positivity to SARS-CoV-2 is associated with a decreased risk of future infection. *medRxiv*. 2020 Dec 20 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33354682>
20. Hansen CH, Michlmayr D, Gubbels SM, Molbak K, Ethelberg S. Assessment of protection against reinfection with SARS-CoV-2 among 4 million PCR-tested individuals in Denmark in 2020: a population-level

observational study. Lancet. 2021 Mar 27;397(10280):1204-12. Available at:
<https://www.ncbi.nlm.nih.gov/pubmed/33743221>

21. Chia WN, Zhu F, Ong SWX, Young BE, Fong SW, Le Bert N, et al. Dynamics of SARS-CoV-2 neutralising antibody responses and duration of immunity: a longitudinal study. Lancet Microbe. 2021 Mar 23 Available at: <https://www.ncbi.nlm.nih.gov/pubmed/33778792>
22. World Health Organization (WHO). Weekly epidemiological update - 25 February 2021. Geneva: WHO; 2021. Available at: <https://www.who.int/publications/m/item/covid-19-weekly-epidemiological-update>